Jiayu Huang, Yi Xia, Yuhang Cheng, Bingyang Shi, Yilei Ma, Ze Tian, Luxiang Wang, Chuanhe Jiang, Haiyang Lu, Weijie Cao, Yang Cao, Xiaodong Mo, Xiaoxia Hu
{"title":"成年b细胞急性淋巴细胞白血病患者在异基因造血干细胞移植前接受或不接受blinatumomab作为桥接治疗的结果","authors":"Jiayu Huang, Yi Xia, Yuhang Cheng, Bingyang Shi, Yilei Ma, Ze Tian, Luxiang Wang, Chuanhe Jiang, Haiyang Lu, Weijie Cao, Yang Cao, Xiaodong Mo, Xiaoxia Hu","doi":"10.21147/j.issn.1000-9604.2025.04.08","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 4","pages":"554-557"},"PeriodicalIF":6.3000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444358/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes of adult patients with B-cell acute lymphoblastic leukemia with or without blinatumomab as bridging therapy prior to allogeneic hematopoietic stem cell transplantation.\",\"authors\":\"Jiayu Huang, Yi Xia, Yuhang Cheng, Bingyang Shi, Yilei Ma, Ze Tian, Luxiang Wang, Chuanhe Jiang, Haiyang Lu, Weijie Cao, Yang Cao, Xiaodong Mo, Xiaoxia Hu\",\"doi\":\"10.21147/j.issn.1000-9604.2025.04.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9882,\"journal\":{\"name\":\"Chinese Journal of Cancer Research\",\"volume\":\"37 4\",\"pages\":\"554-557\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444358/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21147/j.issn.1000-9604.2025.04.08\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2025.04.08","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Outcomes of adult patients with B-cell acute lymphoblastic leukemia with or without blinatumomab as bridging therapy prior to allogeneic hematopoietic stem cell transplantation.
期刊介绍:
Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013.
CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.